Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7XAF

The crystal structure of TrkA kinase in complex with 4^6,14-dimethyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-10-oxo-5-oxa-11,14-diaza-1(3,6)-imidazo[1,2-b]pyridazina-4(1,3)-benzenacyclo- tetradecaphan-2-yne-45-carboxamide

7XAF の概要
エントリーDOI10.2210/pdb7xaf/pdb
分子名称High affinity nerve growth factor receptor, 4^6,14-dimethyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-10-oxo-5-oxa-11,14-diaza-1(3,6)-imidazo[1,2-b]pyridazina-4(1,3)-benzenacyclo-tetradecaphan-2-yne-45-carboxamide (2 entities in total)
機能のキーワードtrka, transferase inhibitor, transferase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
由来する生物種Homo sapiens (human)
タンパク質・核酸の鎖数1
化学式量合計34577.83
構造登録者
Zhang, Z.M.,Wang, Y.J. (登録日: 2022-03-17, 公開日: 2022-06-01, 最終更新日: 2023-11-29)
主引用文献Wang, Z.,Wang, J.,Wang, Y.,Xiang, S.,Song, X.,Tu, Z.,Zhou, Y.,Zhang, Z.M.,Zhang, Z.,Ding, K.,Lu, X.
Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.
J.Med.Chem., 65:6325-6337, 2022
Cited by
PubMed Abstract: Tropomyosin receptor kinase (TRK) secondary mutations mediating acquired resistance, especially at the solvent-front (SF) and the DFG motif, represent an unmet clinical need. Small-molecule macrocyclic kinase inhibitors have displayed significant advantages in overcoming clinical resistance driven by kinase mutations; however, all reported small-molecule macrocyclic TRK inhibitors are all type I inhibitors and are therefore much more sensitive to SF than xDFG mutations. Novel therapeutics for patients with xDFG resistance mutations are urgently needed. We report the first highly selective macrocycle-based potent type II TRK inhibitor, , that exhibits high inhibitory potency toward various TRK fusion protein variants as well as wild type. exhibited potent antiproliferative activity against Ba/F3 cells harboring CD74-TRKA and ETV6-TRKC with half-maximum inhibitory concentration (IC) values of 6 and 1.7 nM, respectively. More importantly, also showed potent antiproliferative activity against a panel of SF mutants (IC = 5.6-110 nM) and displayed extraordinary kinome selectivity.
PubMed: 35426680
DOI: 10.1021/acs.jmedchem.2c00308
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (3.00118200625 Å)
構造検証レポート
Validation report summary of 7xaf
検証レポート(詳細版)ダウンロードをダウンロード

229380

件を2024-12-25に公開中

PDB statisticsPDBj update infoContact PDBjnumon